KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Net Income towards Common Stockholders (2018 - 2025)

Amneal Pharmaceuticals has reported Net Income towards Common Stockholders over the past 8 years, most recently at $49.6 million for Q4 2025.

  • Quarterly results put Net Income towards Common Stockholders at $49.6 million for Q4 2025, up 339.0% from a year ago — trailing twelve months through Dec 2025 was $127.9 million (up 273.17% YoY), and the annual figure for FY2025 was $127.9 million, up 209.45%.
  • Net Income towards Common Stockholders for Q4 2025 was $49.6 million at Amneal Pharmaceuticals, up from $18.1 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for AMRX hit a ceiling of $49.6 million in Q4 2025 and a floor of -$120.8 million in Q2 2022.
  • Median Net Income towards Common Stockholders over the past 5 years was $2.3 million (2021), compared with a mean of -$7.5 million.
  • Peak annual rise in Net Income towards Common Stockholders hit 460.06% in 2023, while the deepest fall reached 2176.69% in 2023.
  • Amneal Pharmaceuticals' Net Income towards Common Stockholders stood at -$6.4 million in 2021, then soared by 32.05% to -$4.3 million in 2022, then plummeted by 2176.69% to -$98.6 million in 2023, then surged by 78.97% to -$20.7 million in 2024, then skyrocketed by 339.0% to $49.6 million in 2025.
  • The last three reported values for Net Income towards Common Stockholders were $49.6 million (Q4 2025), $18.1 million (Q3 2025), and $35.6 million (Q2 2025) per Business Quant data.